Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection
View HTML
Toggle Summary Intersect ENT Added to Russell 2000 Index
MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of
View HTML
Toggle Summary Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contour Steroid Releasing Sinus Implant
Study Builds on the Extensive Clinical Evidence for Steroid Releasing Sinus Implants MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center
View HTML
Toggle Summary Intersect ENT Announces Changes to Board of Directors
MENLO PARK, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the resignations of Rick Anderson, PTV Healthcare Capital, and Mark Fletcher, Medtronic,
View HTML
Toggle Summary Intersect ENT Announces Closing of its Initial Public Offering
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of
View HTML
Toggle Summary Intersect ENT Announces Exercise of Underwriters' Option and the Closing of Its Public Offering
Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and
View HTML
Toggle Summary Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the
View HTML
Toggle Summary Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced U.S.
View HTML
Toggle Summary Intersect ENT Announces Preliminary 2014 Financial Results
MENLO PARK, Calif. , Jan. 12, 2015 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that it expects to report revenue for the fourth quarter of 2014 in the range of $13.2 to
View HTML
Toggle Summary Intersect ENT Announces Preliminary Q2 Revenue and Business Update
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced preliminary revenue for the second quarter 2016 of approximately $19.3 million , an increase of 27% from
View HTML